➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Moodys
Baxter
Dow
Colorcon

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AMOXIL

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Amoxil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00778050 ↗ Bioequivalence Study of Amoxicillin Dispersible 600 mg Tablets Under Fasting Conditions Completed Ranbaxy Laboratories Limited N/A 2002-10-01 This study compared the relative bioavailability (rate and extent of absorption) of amoxicillin tablets for oral suspension 600 mg by Ranbaxy Laboratories Limited with that of Amoxil ┬« for oral suspension 400 mg/ 5 mL by SmithKline Beecham Pharmaceuticals following single oral dose (600 mg) in healthy, adult, subjects under fasting conditions using a randomized two-way crossover design.
NCT01431989 ↗ Amoxicillin Bioequivalence Study Brazil - Fast Completed GlaxoSmithKline Phase 1 2011-05-01 This study is prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods. The volunteers received, in each period, the reference or the test formulation, according to the randomization list, under fasting conditions, in order to evaluate if the reference and test formulations are bioequivalent.
NCT02045251 ↗ An Open-Label Trial Of Reduced- Dose Pylera, Amoxicillin, and Esomeprazole in the Treatment Of Helicobacter Pylori Infection Withdrawn American University of Beirut Medical Center Phase 4 2013-06-01 Over the years, it has become clear that the first-line triple therapy is losing efficacy worldwide. A capsule containing 3 agents (Pylera┬«) containing 125mg metronidazole, 140mg bismuth subcitrate potassium, and 125mg tetracycline was made available. The efficacy of the Pylera capsule was studied in a randomized control trial, in which a quadruple Pylera therapy (Pylera capsule and a PPI) was evaluated against the standard triple regimen. In the study, 3 three-in-one capsules were taken four times daily (after meals and at bedtime). Given the above, we aim at assessing the effectiveness of fewer pills per day of the Pylera capsule (3 Pylera capsules supplemented with the addition of amoxicillin and esomeprazole twice daily; sum of 10 pills/day for 10 days) in the eradication of H. pylori.
NCT03031210 ↗ Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia. Not yet recruiting St. Justine's Hospital Phase 2/Phase 3 2017-03-01 The aim of this study will be to evaluate whether a twice-daily antibiotic regimen is non-inferior to a thrice-daily regimen for the treatment of non-severe community acquired pneumonia in children presenting at a paediatric Emergency Department (ED).
NCT03094247 ↗ Feeding Malnourished Children Different Types of Fatty Acids to Promote Neurocognitive Development Recruiting Cornell University N/A 2017-09-01 An appropriate balance of omega-6 and omega-3 fatty acids is important for support of neurocognitive development in healthy infants and toddlers. In young children recovering from severe acute malnutrition (SAM), excess omega-6 intake depletes omega-3 fatty acid status. This research will evaluate how novel ready-to-use therapeutic foods (RUTF) with balanced fatty acids improve the metabolic and neurocognitive effects in young children in Malawi recovering from SAM, yielding new knowledge that also has implications for development of well-nourished children.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Amoxil

Condition Name

Condition Name for Amoxil
Intervention Trials
Aggressive Periodontitis, Generalized 1
Healthy 1
Acute Tonsillitis 1
Gastritis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Amoxil
Intervention Trials
Infection 2
Communicable Diseases 2
Gastritis 1
Pneumonia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Amoxil

Trials by Country

Trials by Country for Amoxil
Location Trials
Brazil 3
United States 2
Lebanon 1
Egypt 1
Malawi 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Amoxil
Location Trials
New York 1
North Dakota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Amoxil

Clinical Trial Phase

Clinical Trial Phase for Amoxil
Clinical Trial Phase Trials
Phase 4 6
Phase 2/Phase 3 2
Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Amoxil
Clinical Trial Phase Trials
Not yet recruiting 5
Completed 5
Recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Amoxil

Sponsor Name

Sponsor Name for Amoxil
Sponsor Trials
University of Campinas, Brazil 1
China Academy of Chinese Medical Sciences 1
Cornell University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Amoxil
Sponsor Trials
Other 20
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
AstraZeneca
Mallinckrodt
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.